TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Mean maximum ST-segment depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Heart rate variation from onset to maximum ST-segment depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction of ischemic episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incident DM
Endpoint domain: Mortality/survival
Primary endpoint: MPA exposure >40 mg/h per L
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IMPDH activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall safety
Endpoint domain: Adverse events/effects
Primary endpoint: Nitrotyrosine production
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activity of GPX
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activity of Cat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AOFAS score at two weeks after operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AOFAS score at one year after operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression to kidney failure
Endpoint domain: Mortality/survival
Primary endpoint: symptomatic VTE rates
Endpoint domain: Mortality/survival
Primary endpoint: total expected cost per patient
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: incremental cost effectiveness of enoxaparin 40 mg versus placebo
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Reliability of active and passive range of motion (ROM) measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary composite outcome of fatal and nonfatal major cardiovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Patient satisfaction with wound appearance
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Narcotic requirement in recovery
Endpoint domain: Adverse events/effects
Primary endpoint: risk of disease recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Levels of CgA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prescription opioid usage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days to stop using oral opioids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in mean number of lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Platelet aggregation percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Thromboxane B(2) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean fasting blood glucose (FBG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Neuropsychological impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Patient preference for contact lens modality
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: serum cystatin C increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Target-vessel revascularisation (TVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: NVP plasma concentration at 12 h (C12) <3.1 mg/l
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median CD4+ T‐cell count rise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: proportion with viral load <50 copies/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: 1,25-Dihydroxyvitamin D(3) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Osteocalcin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Length of time to recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean HR reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: HRV measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Matsuda Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Postprandial area under the curve for glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Societal burden of Alzheimer's Disease (AD)
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: ST-segment elevation of 0.1 mV or greater
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: incidence of abnormal cytology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Timetrial performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FVC and FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Narcotic use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Rate of self-referral blood tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of diagnosis of type 2 diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cost per new case of type 2 diabetes diagnosed
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Observer's Assessment of Alertness/Sedation score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Bacterial Vaginosis (BV) prevalence in women with infertility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in intermittent claudication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of dentinal carious lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Dental outcomes
Primary endpoint: Cavitated carious lesions prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Dental outcomes
Primary endpoint: Extent of HSPM lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Dental outcomes
Primary endpoint: radiographic progression-free survival
Endpoint domain: Mortality/survival
Primary endpoint: time to chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Carboplatin concentration in retinas
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Signs of tissue damage
Endpoint domain: Adverse events/effects
Primary endpoint: VP gap size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hypernasality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average VO2 after exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma lactate concentration ([La]) at the end of exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Average heart rate (HR) during exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: PO2 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glaucoma stabilization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall photodamage improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Median AK complete responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Histological accuracy rates of biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inhibition of CYP1A2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean 24-h intragastric pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Proportion of time when pH <4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Breastfeeding at 1 month
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Breastfeeding without formula at 1 month
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Readmission rates
Endpoint domain: Adverse events/effects
Primary endpoint: drain fluid production
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Angina at 2 years
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Overall G2-4 CNS adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Abnormal dreams
Endpoint domain: Adverse events/effects
Primary endpoint: Nervousness
Endpoint domain: Adverse events/effects
Primary endpoint: mean jitter values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in carotid IMT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in low-density lipoprotein cholesterol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cesarean deliveries performed because of nonreassuring fetal status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Overall cesarean delivery rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Need for resuscitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma aldosterone concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: urinary excretion of aldosterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Quality of Life (QOL) measured by SF-36 physical component scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Delayed improvement in health transition
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of return to normal daily activities
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: delivery and postnatal care service utilization
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Energy Intake (EI) from fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Energy Intake (EI) from carbohydrates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Qualeffo physical function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Maternal anemia prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of patients missed on resident rounds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of sign-out
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Continuity of care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of rescue-free days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treadmill walking time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peri-implant PI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BOP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MBL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3-year survival probability of molars
Endpoint domain: Mortality/survival
Primary endpoint: BIS level control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptoms of PTSD and comorbid depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tpCR rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma levels of NT-proANP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: serum levels of PINP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: New-onset myocardial infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Thyroid remnant volume reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intensity of allergic reaction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Need for higher allergen concentration to trigger ocular signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: mean mRS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of patients with worsened motor deficits
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean number of days stayed in school for lunch
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Proportion of students remaining in school for lunch every day
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: muscle mitochondrial respiration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Abundance of microbial species associated with periodontal disease and dental caries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Visual acuity preservation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Size of the neovascular membrane
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Need for renal replacement therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Resolution of cervicitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: preterm birth risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Baseline aldosterone concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Baseline renin activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Responses of angiotensin II to ACEI treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Reduction in functional decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nursing home admission rates
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: number of surfaces with plaque
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in smoking levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in monthly seizure frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Improvement in patient's overall condition
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Job tenure duration
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Improvement in targeted work behavior problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiovascular measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ratings indicative of abuse potential
Endpoint domain: Adverse events/effects
Primary endpoint: IL-6 mRNA expression changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Frequency of vitamin D sufficiency after supplementation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Frequency of vitamin D sufficiency in infants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: ADHD‐RS‐IV total scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiac auscultation accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Concentrations of plasma cortisol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Concentrations of plasma glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Concentrations of plasma lactate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: DNA damage in exfoliated buccal cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical deterioration
Endpoint domain: Adverse events/effects
Primary endpoint: antibiotic escalation
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum carotid intima-media thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Maximum aortic intima-media thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Brachial artery flow-mediated dilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Proliferation rates of colorectal mucosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum lithocholic acid levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lung function reductions (FVC, FEV1, PEF, MEF 25, MEF 50, MEF 75)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Bone ingrowth grades
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adverse outcomes
Endpoint domain: Adverse events/effects
Primary endpoint: time of return to work activities
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: success rates within 24 and 48 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CD8(+) T cell apoptosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: periprocedural platelet reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: PMI rates
Endpoint domain: Adverse events/effects
Primary endpoint: Diagnostic accuracy of the ILR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility and safety of axillary access for ILR implantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aesthetic superiority and potential for minimizing scarring
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: serum ferritin concentration improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum transferrin receptor concentration improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume of allogeneic RBC transfused
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Blood loss volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Retinal arterial diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RBC velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RBC flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fibrotic posterior capsule opacification (PCO) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevention of dry socket
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall success rate of radial artery catheterization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Time needed to cannulate the radial artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Cardiac 18F-FDG uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severe Anemia (grade III/IV)
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in microalbuminuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: long-term outcome of treatments for tennis elbow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cessation of bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anoscopy inflammation score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight loss of ≥ 5%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight loss of ≥ 10%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HBV test reporting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: perfusion parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: thickness of the subcutaneous tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: echogenicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: presence of edemas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes